Novel Targets of Current Analgesic Drug Development




14.

Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 1998;345:145–53.PubMed


15.

Liu C, Walker JM. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. J Neurophysiol. 2006;96:2984–94.PubMed


16.

Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998;76:189–99.PubMed


17.

Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 2005;48:658–72.PubMed


18.

Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008;109:101–10.PubMed


19.

Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–72.PubMed


20.

Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006;104:1040–6.PubMed


21.

Borgelt L, Franson K, Nussbaum A, Wang G. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33:195–209.PubMed


22.

Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Phil Trans R Soc B. 2012;367:3353–63.PubMedCentralPubMed


23.

Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160:467–79.PubMedCentralPubMed


24.

Groblewski T, et al. Pre-clinical pharmacological properties of novel peripherally-acting CB1-CB2 agonists. In: 20th annual symposium on the cannabinoids. Research Triangle Park: Int. Cannabinoid Research Society; 2010, p. 37.


25.

Kalliomäki J, Annas P, Huizar K, Clarke C, Zettergren A, Karlsten R, Segerdahl M. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2013;40:212–8.PubMed


26.

Kalliomaki J, Seqerdahl M, Webster L, Reimfelt A, Huizar K, Annas P, Karlsten R, Quiding H. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. Scan J Pain. 2013;4:17–22.


27.

Fanger CM, del Camino D, Moran MM. TRPA1 as an analgesic target. Open Drug Discov J. 2010;2:64–70.


28.

Radresa O, Dahllöf H, Nyman E, Nolting A, Alberta JS, Raboisson P. Roles of TRPA1 in pain pathophysiology and implications for the development of a new class of analgesic drugs. Open Pain J. 2013;6:S137–53.


29.

Trevisani M, Gatti R. TRPV1 antagonists as analgesic agents. Open Pain J. 2013;6:S108–18.


30.

Clapham DE. TRP channels as cellular sensors. Nature. 2003;426:517–24.PubMed


31.

Montell C. Drosophila TRP channels. Pflugers Arch. 2005;451:19–28.PubMed


32.

Lennertz RC, Kossyreva EA, Smith AK, Stucky CL. TRPA1 mediates mechanical sensitization in nociceptors during inflammation. PLoS One. 2012;7:e43597. doi:10.​1371/​journal.​pone.​0043597.PubMedCentralPubMed


33.

Nassini R, Pedretti P, Moretto N, Fusi C, Carnini C, et al. Transient receptor potential Ankyrin 1 channel localized to non-neuronal airway cells promotes non-neurogenic inflammation. PLoS One. 2012;7(8):e42454. doi:10.​1371/​journal.​pone.​0042454.PubMedCentralPubMed


34.

Kremeyer B, Lopera F, Cox JJ, Momin A, Rugiero F, Marsh S, Woods CG, Jones NG, Paterson KJ, Fricer FR, Villegas A, Acosta N, Pineda-Trujillo NG, Ramirez JD, Zea J, Burley MW, Bedoya G, Bennett DL, Wood JN, Ruiz-Linares A. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron. 2010;66(5):671–80.PubMed


35.

Matta JA, Cornett PM, Miyares RL, Abe K, Sahibzada N, Ahern GP. General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci U S A. 2008;105(25):8784–9.PubMedCentralPubMed


36.

Kosugi M, Nakatsuka T, Fujita T, Kuroda Y, Kumamoto E. Activation of TRPA1 channel facilitates excitatory synaptic transmission in substantia gelatinosa neurons of the adult rat spinal cord. J Neurosci. 2007;27:4443–51.PubMed


37.

Corey DP, Garcia-Anoveros J, Holt JR, Kwan KY, Lin SY, Vollrath MA, Amalfitano A, Cheung EL, Derfler BH, Duggan A, Geleoc GS, Gray PA, Hoffman MP, Rehm HL, Tamasauskas D, Zhang DS. TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells. Nature. 2004;432(7018):723–30.PubMed

Only gold members can continue reading. Log In or Register to continue

Sep 18, 2016 | Posted by in ANESTHESIA | Comments Off on Novel Targets of Current Analgesic Drug Development
Premium Wordpress Themes by UFO Themes